Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Research Article

Total Flavonoids Isolated from the Leaves of Eucommia ulmoides Augment Peak Bone Mass in Female Rats and Show no Side Effects in Other Organs

Author(s): Yun Zhang, Mingzhen Yang, Ningli Li, Qin Li, Yingying Li and Yuankun Zhai*

Volume 30, Issue 30, 2024

Published on: 03 July, 2024

Page: [2410 - 2423] Pages: 14

DOI: 10.2174/0113816128298755240613100018

Price: $65

Abstract

Introduction: Eucommia ulmoides is a unique monophyletic and tertiary relict in China and is listed as a national second-class precious protected tree species. Eucommia ulmoides, recognized as a traditional Chinese medicine, can tonify the liver and kidneys and strengthen bones and muscles. Modern pharmacological research has proved that Eucommia ulmoides has multiple osteoprotective effects, including prohibiting the occurrence of osteoporosis and arthritis and enhancing the healing of bone fractures and bone defects.

Aim: To check its osteotropic effects, which may provide ideas for its potential use for the development of novel drugs to treat osteoporosis, this study evaluated the effect of total flavonoids from Eucommia ulmoides leaves (TFEL) on the acquisition of Peak Bone Mass (PBM) in young female rats.

Materials and Methods: TFEL was isolated, and its purity was confirmed by using a UV spectrophotometer. TFEL with a purity of 85.09% was administered to 6-week-old female rats by oral gavage at a low (50), mid (100), or high (200 mg/kg/d) dose, and the control group was administrated only with the same volume of water. After 13 weeks of treatment, the rats were sacrificed, and serum, different organs, and limb bones (femurs and tibias) were harvested, and the bone turnover markers, organ index, Bone Mineral Density (BMD), biomechanical property, and microstructure parameters were assayed. Furthermore, molecular targets were screened, and network pharmacology analyses were conducted to reveal the potential mechanisms of action of TFEL.

Results: Oral administration of TFEL for 13 weeks decreased the serum level of bone resorption marker TRACP-5b. As revealed by micro-computer tomography analysis, it elevated BMD even at a low dose (50 mg/kg/d) and improved the microstructural parameters, which were also confirmed by H&E histological staining. However, TFEL showed no effects on body weights, organ index, and micromorphology in the uterus. In our network pharmacology study, an intersection analysis screened out 64 shared targets, with quercetin, kaempferol, naringenin, and apigenin regulating the greatest number of targets associated with osteoporosis. Flavonoids in Eucommia ulmoides inhibited the occurrence of osteoporosis potentially through targeting signaling pathways for calcium, VEGF, IL-17, and NF-κB. Furthermore, AKT1, EGFR, PTGS2, VEGFA, and CALM were found to be potentially important target genes for the osteoprotective effects of flavonoids in Eucommia ulmoides.

Conclusion: The above results suggested that TFEL can be used to elevate the peak bone mass in adolescence in female individuals, which may prevent the occurrence of postmenopausal osteoporosis, and the good safety of TFEL also suggests that it can be used as a food additive for daily life to improve the bone health.

« Previous
[1]
Lin YH, Wang CF, Chiu H, et al. Air pollutants interaction and gender difference on bone mineral density t-score in taiwanese adults. Int J Environ Res Public Health 2020; 17(24): 9165.
[http://dx.doi.org/10.3390/ijerph17249165] [PMID: 33302461]
[2]
Dai W, Zhang H, Zhong ZA, et al. β-ecdysone augments peak bone mass in mice of both sexes. Clin Orthop Relat Res 2015; 473(8): 2495-504.
[http://dx.doi.org/10.1007/s11999-015-4246-5] [PMID: 25822452]
[3]
Johnston CC Jr, Slemenda CW. Determinants of peak bone mass. Osteoporos Int 1993; 3(S1) (Suppl. 1): 54-5.
[http://dx.doi.org/10.1007/BF01621864] [PMID: 8461578]
[4]
Xi HR, Ma HP, Yang FF, et al. Total flavonoid extract of Epimedium herb increases the peak bone mass of young rats involving enhanced activation of the AC10/cAMP/PKA/CREB pathway. J Ethnopharmacol 2018; 223: 76-87.
[http://dx.doi.org/10.1016/j.jep.2018.05.023] [PMID: 29783019]
[5]
Bonjour JP, Chevalley T, Ferrari S, Rizzoli R. The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publica Mex 2009; 51 (Suppl. 1): S5-S17.
[http://dx.doi.org/10.1590/S0036-36342009000700004] [PMID: 19287894]
[6]
Wu D, Cline-Smith A, Shashkova E, Perla A, Katyal A, Aurora R. T-cell mediated inflammation in postmenopausal osteoporosis. Front Immunol 2021; 12: 687551.
[http://dx.doi.org/10.3389/fimmu.2021.687551] [PMID: 34276675]
[7]
Zhou T, Gai Z, Gao X, Li L. The potential mechanism of exercise combined with natural extracts to prevent and treat postmenopausal osteoporosis. J Healthc Eng 2021; 2021: 1-9.
[http://dx.doi.org/10.1155/2021/2852661] [PMID: 34956564]
[8]
Zhai Y, Wang Q, Li Y, et al. The higher osteoprotective activity of psoralidin in vivo than coumestrol is attributed by its presence of an isopentenyl group and through activated PI3K/Akt axis. Biomed Pharmacother 2018; 102: 1015-24.
[http://dx.doi.org/10.1016/j.biopha.2018.03.166] [PMID: 29710518]
[9]
Wang CY, Tang L, He JW, Li J, Wang YZ. Ethnobotany, phytochemistry and pharmacological properties of Eucommia ulmoides: A review. Am J Chin Med 2019; 47(2): 259-300.
[http://dx.doi.org/10.1142/S0192415X19500137] [PMID: 30857406]
[10]
Zhang S, Yu Z, Xia J, et al. Anti-parkinson’s disease activity of phenolic acids from Eucommia ulmoides oliver leaf extracts and their autophagy activation mechanism. Food Funct 2020; 11(2): 1425-40.
[http://dx.doi.org/10.1039/C9FO02288K] [PMID: 31971191]
[11]
Guan M, Pan D, Zhang M, Leng X, Yao B. The aqueous extract of eucommia leaves promotes proliferation, differentiation, and mineralization of osteoblast-like MC3T3-E1 Cells. Evid Based Complement Alternat Med 2021; 2021: 1-12.
[http://dx.doi.org/10.1155/2021/3641317] [PMID: 34249129]
[12]
Lin J, Fan Y, Mehl C, et al. Eucommia ulmoides Oliv. antagonizes H2O2-induced rat osteoblastic MC3T3-E1 apoptosis by inhibiting expressions of caspases 3, 6, 7, and 9. J Zhejiang Univ Sci B 2011; 12(1): 47-54.
[http://dx.doi.org/10.1631/jzus.B1000057] [PMID: 21194186]
[13]
Dancause KN, Cao XJ, Veru F, et al. Brief communication: Prenatal and early postnatal stress exposure influences long bone length in adult rat offspring. Am J Phys Anthropol 2012; 149(2): 307-11.
[http://dx.doi.org/10.1002/ajpa.22117] [PMID: 22826037]
[14]
Liu H, Zhu R, Liu C, et al. Evaluation of decalcification techniques for rat femurs using HE and immunohistochemical staining. BioMed Res Int 2017; 2017: 1-6.
[http://dx.doi.org/10.1155/2017/9050754] [PMID: 28246608]
[15]
Ru JL, Li P, Wang JN. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J Cheminformatics 2014.
[http://dx.doi.org/10.1186/1758-2946-6-13]
[16]
Takamura C, Hirata T, Yamaguchi Y, et al. Studies on the chemical constituents of green leaves of Eucommia ulmoides Oliv. J Nat Med 2007; 61(2): 220-1.
[http://dx.doi.org/10.1007/s11418-006-0027-5]
[17]
Jian-kun Y, Xiang-yu Z, Xu-liu S, Li-qin D. Study on flavonoids from leaves of Eucommia ulmoides. Zhongguo Xiandai Zhongyao 2021; 23(04): 599-604.
[http://dx.doi.org/10.13313/j.issn.1673-4890.20201006003]
[18]
Kim S, Chen J, Cheng T, et al. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res 2021; 49(D1): D1388-95.
[http://dx.doi.org/10.1093/nar/gkaa971] [PMID: 33151290]
[19]
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7: 42717.
[http://dx.doi.org/10.1038/srep42717]
[20]
Daina A, Michielin O, Zoete V. Swisstargetprediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 2019; 47(W1): W357-64.
[http://dx.doi.org/10.1093/nar/gkz382] [PMID: 31106366]
[21]
Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res 2018; 46(D1): D1074-82.
[http://dx.doi.org/10.1093/nar/gkx1037] [PMID: 29126136]
[22]
Stelzer G, Rosen N, Plaschkes I. The genecards suite: From gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics 2016; 54(1): 30-3.
[http://dx.doi.org/10.1002/cpbi.5]
[23]
Amberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): A knowledgebase of human genes and genetic phenotypes. Curr Protoc Bioinformatics 2017; 58(1): 2.1-12.
[http://dx.doi.org/10.1002/cpbi.27] [PMID: 28654725]
[24]
Clough E, Barrett T. The gene expression omnibus database Methods Mol Biol 2016; 1418(Chapter 5): 93-110.
[25]
Benisch P, Schilling T, Klein-Hitpass L. The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. Plos One 2012; 7(9): e45142.
[http://dx.doi.org/10.1371/journal.pone.0045142]
[26]
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47(D1): D607-13.
[http://dx.doi.org/10.1093/nar/gky1131] [PMID: 30476243]
[27]
Kang P, Wu ZM, Zhong Y. A network pharmacology and molecular docking strategy to explore potential targets and mechanisms underlying the effect of curcumin on osteonecrosis of the femoral head in systemic lupus erythematosus. BioMed Res Int 2021; 2021: 5538643.
[http://dx.doi.org/10.1155/2021/5538643]
[28]
Zhou YY, Zhou B, Pache L. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019; 10(1): 1523.
[http://dx.doi.org/10.1038/s41467-019-09234-6]
[29]
Pinto D, Alshahrani M, Chapurlat R, et al. The global approach to rehabilitation following an osteoporotic fragility fracture: A review of the rehabilitation working group of the International Osteoporosis Foundation (IOF) committee of scientific advisors. Osteoporos Int 2022; 33(3): 527-40.
[http://dx.doi.org/10.1007/s00198-021-06240-7] [PMID: 35048200]
[30]
Chen P, Li Z, Hu Y. Prevalence of osteoporosis in China: A meta-analysis and systematic review. BMC Public Health 2016; 16(1): 1039.
[http://dx.doi.org/10.1186/s12889-016-3712-7] [PMID: 27716144]
[31]
Zhao J, Zeng L, Wu M. Efficacy of Chinese patent medicine for primary osteoporosis: A network meta-analysis. Complement Ther Clin Pract 2021; 44: 101419.
[http://dx.doi.org/10.1016/j.ctcp.2021.101419]
[32]
Li J, Sun K, Qi B, et al. An evaluation of the effects and safety of Zuogui pill for treating osteoporosis: Current evidence for an ancient Chinese herbal formula. Phytother Res 2021; 35(4): 1754-67.
[http://dx.doi.org/10.1002/ptr.6908] [PMID: 33089589]
[33]
Trajanoska K, Schoufour JD, de Jonge EAL, et al. Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam Study. Bone 2018; 114: 116-24.
[http://dx.doi.org/10.1016/j.bone.2018.06.004] [PMID: 29885926]
[34]
Aspray TJ, Bowring C, Fraser W, et al. National osteoporosis society vitamin D guideline summary. Age Ageing 2014; 43(5): 592-5.
[http://dx.doi.org/10.1093/ageing/afu093] [PMID: 25074538]
[35]
Vidal M, Thibodaux RJ, Neira LFV, Messina OD. Osteoporosis: A clinical and pharmacological update. Clin Rheumatol 2019; 38(2): 385-95.
[http://dx.doi.org/10.1007/s10067-018-4370-1] [PMID: 30542797]
[36]
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288(3): 321-33.
[http://dx.doi.org/10.1001/jama.288.3.321] [PMID: 12117397]
[37]
Weaver CM, Gordon CM, Janz KF, et al. The national osteoporosis foundation’s position statement on peak bone mass development and lifestyle factors: A systematic review and implementation recommendations. Osteoporos Int 2016; 27(4): 1281-386.
[http://dx.doi.org/10.1007/s00198-015-3440-3] [PMID: 26856587]
[38]
Chevalley T, Rizzoli R. Acquisition of peak bone mass. Best Pract Res Clin Endocrinol Metab 2022; 36(2): 101616.
[http://dx.doi.org/10.1016/j.beem.2022.101616] [PMID: 35125324]
[39]
Hernandez CJ, Beaupré GS, Carter DR. A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis. Osteoporos Int 2003; 14(10): 843-7.
[http://dx.doi.org/10.1007/s00198-003-1454-8] [PMID: 12904837]
[40]
Zhu X, Zheng H. Factors influencing peak bone mass gain. Front Med 2021; 15(1): 53-69.
[http://dx.doi.org/10.1007/s11684-020-0748-y] [PMID: 32519297]
[41]
Karlsson MK, Rosengren BE. Exercise and peak bone mass. Curr Osteoporos Rep 2020; 18(3): 285-90.
[http://dx.doi.org/10.1007/s11914-020-00588-1] [PMID: 32249382]
[42]
Nguyen HG, Pham MTD, Ho-Pham LT, Nguyen TV. Lean mass and peak bone mineral density. Osteoporos Sarcopenia 2020; 6(4): 212-6.
[http://dx.doi.org/10.1016/j.afos.2020.10.001] [PMID: 33426311]
[43]
Luo X, Wu J, Li Z, et al. Safety evaluation of Eucommia ulmoides extract. Regul Toxicol Pharmacol 2020; 118: 104811.
[http://dx.doi.org/10.1016/j.yrtph.2020.104811] [PMID: 33122045]
[44]
Huang Q, Zhang F, Liu S, Jiang Y, Ouyang D. Systematic investigation of the pharmacological mechanism for renal protection by the leaves of Eucommia ulmoides Oliver using UPLC-Q-TOF/MS combined with network pharmacology analysis. Biomed Pharmacother 2021; 140: 111735.
[http://dx.doi.org/10.1016/j.biopha.2021.111735] [PMID: 34020251]
[45]
Xing YY, Wang JY, Wang K, et al. Inhibition of rheumatoid arthritis using bark, leaf, and male flower extracts of Eucommia ulmoides. Evid Based Complement Alternat Med 2020; 2020: 1-11.
[http://dx.doi.org/10.1155/2020/3260278] [PMID: 32855647]
[46]
Zhou Y, Liang M, Li W, et al. Protective effects of Eucommia ulmoides Oliv. bark and leaf on amyloid β-induced cytotoxicity. Environ Toxicol Pharmacol 2009; 28(3): 342-9.
[http://dx.doi.org/10.1016/j.etap.2009.05.012] [PMID: 21784025]
[47]
Zhu MQ, Sun RC. Eucommia ulmoides Oliver: A potential feedstock for bioactive products. J Agric Food Chem 2018; 66(22): 5433-8.
[http://dx.doi.org/10.1021/acs.jafc.8b01312] [PMID: 29745662]
[48]
Greenway F, Liu Z, Yu Y, Gupta A. A clinical trial testing the safety and efficacy of a standardized Eucommia ulmoides Oliver bark extract to treat hypertension. Altern Med Rev 2011; 16(4): 338-47.
[PMID: 22214253]
[49]
He X, Wang J, Li M, et al. Eucommia ulmoides Oliv.: Ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol 2014; 151(1): 78-92.
[http://dx.doi.org/10.1016/j.jep.2013.11.023] [PMID: 24296089]
[50]
Pang XG, Cong Y, Bao NR, Li YG, Zhao JN. Quercetin stimulates bone marrow mesenchymal stem cell differentiation through an estrogen receptor-mediated pathway. BioMed Res Int 2018; 2018; 1-11.
[http://dx.doi.org/10.1155/2018/4178021] [PMID: 29736392]
[51]
Li M, Zhang C, Li X, Lv Z, Chen Y, Zhao J. Isoquercitrin promotes the osteogenic differentiation of osteoblasts and BMSCs via the RUNX2 or BMP pathway. Connect Tissue Res 2019; 60(2): 189-99.
[http://dx.doi.org/10.1080/03008207.2018.1483358] [PMID: 29852784]
[52]
Li Z, Zhang J, Ren X, Liu Q, Yang X. The mechanism of quercetin in regulating osteoclast activation and the PAR2/TRPV1 signaling pathway in the treatment of bone cancer pain. Int J Clin Exp Pathol 2018; 11(11): 5149-56.
[PMID: 31949595]
[53]
Adhikary S, Choudhary D, Ahmad N, et al. Dietary flavonoid kaempferol inhibits glucocorticoid-induced bone loss by promoting osteoblast survival. Nutrition 2018; 53: 64-76.
[http://dx.doi.org/10.1016/j.nut.2017.12.003] [PMID: 29655780]
[54]
Wang QL, Huo XC, Wang JH, et al. Rutin prevents the ovariectomy-induced osteoporosis in rats. Eur Rev Med Pharmacol Sci 2017; 21(8): 1911-7.
[PMID: 28485786]
[55]
Zhao X, Wang Y, Nie Z, et al. Eucommia ulmoides leaf extract alters gut microbiota composition, enhances short‐chain fatty acids production, and ameliorates osteoporosis in the senescence‐accelerated mouse P6 (SAMP6) model. Food Sci Nutr 2020; 8(9): 4897-906.
[http://dx.doi.org/10.1002/fsn3.1779] [PMID: 32994951]
[56]
Oršolić N, Nemrava J, Jeleč Ž. Antioxidative and anti-inflammatory activities of chrysin and naringenin in a drug-induced bone loss model in rats. Int J Mol Sci 2022; 23(5): 2872.
[http://dx.doi.org/10.3390/ijms23052872]
[57]
Pan F, Shao J, Shi CJ, Li Z, Fu W, Zhang J. Apigenin promotes osteogenic differentiation of mesenchymal stem cells and accelerates bone fracture healing via activating Wnt/β-catenin signaling. Am J Physiol Endocrinol Metab 2021; 320(4): E760-71.
[http://dx.doi.org/10.1152/ajpendo.00543.2019] [PMID: 33645251]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy